CanSino Biologics Q1 Loss After Two Profitable Quarters Tests Bullish Profitability Narratives

CanSino Biologics (SEHK:6185) opened Q1 2026 with total revenue of C¥190.3 million and a basic EPS loss of C¥0.16 per share, setting a cautious tone for the latest update. Over the past year, revenue on a trailing twelve month basis has moved from C¥846.3 million in Q4 2024 to C¥1.1 billion in Q1 2026, while trailing EPS has shifted from a loss of C¥1.53 to a much smaller loss of C¥0.00 per share. This puts the focus squarely on how far the company has come in narrowing losses and what that means for margins from here.

See our full analysis for CanSino Biologics.

With the latest figures on the table, the next step is to set these margins and revenue trends against the big narratives investors follow, highlighting where the story holds up and where expectations may need adjusting.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM loss narrows to about C¥1.0 million

• On a trailing twelve month basis, net income excluding extra items is a loss of about C¥1.0 million on C¥1.1b of revenue, compared with a loss of C¥378.9 million on C¥846.3 million of revenue at the end of 2024.
• A notable point for those expecting that earnings can improve is how this trailing loss compares to earlier periods. Prior twelve month losses such as C¥220.3 million in Q1 2025 and C¥166.9 million in Q2 2025 were much larger, which indicates that the earnings profile is moving closer to break even even though profitability is not yet achieved.

Quarterly swing from C¥13.4m profit to C¥40.4m loss

• Q1 2026 shows a loss of C¥40.4 million on C¥190.3 million of revenue, following a profit of C¥13.4 million on C¥375.3 million of revenue in Q4 2025 and C¥27.9 million on C¥310.2 million of revenue in Q3 2025.
• Skeptics highlight the company’s history of losses, and this quarter adds to that view. The shift from Q3 and Q4 2025 profits back to a C¥40.4 million loss in Q1 2026, alongside earlier quarterly losses of C¥11.5 million in Q1 2025 and C¥1.9 million in Q2 2025, shows that profitability on a single quarter basis has not yet settled into a stable pattern, even as the trailing twelve month loss narrows.

Share price below both DCF and analyst target

• The current share price of HK$29.38 sits below a cited DCF fair value of HK$46.41 and also below an analyst price target of HK$48.54. The trailing P/S ratio of 5.7x is lower than the Hong Kong biotechs industry average of 12.6x and the peer average of 31.5x.
• Arguments that the stock has valuation support draw on these comparisons. The gap between HK$29.38 and the DCF fair value of HK$46.41 plus the HK$48.54 analyst target, together with a P/S that is less than half the industry average, indicates that investors are currently paying a lower multiple for each C¥1.1b of trailing revenue, even though the company remains loss making over the last twelve months.

Curious how different investors are interpreting these numbers and what stories they build from them, including both optimism and caution around the loss profile and valuation gap, see what the community is saying about CanSino Biologics 📊 Read the what the Community is saying about CanSino Biologics.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on CanSino Biologics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

If this mix of narrowing losses and uneven quarterly results leaves you on the fence, use the full data to build your own view and move quickly. To understand why some investors are still optimistic, review the 4 key rewards

Explore Alternatives

CanSino Biologics still reports quarterly losses and uneven profitability, with Q1 2026 swinging from recent profits back to a C¥40.4 million loss despite narrowing trailing losses.

If that earnings volatility feels uncomfortable and you want ideas with steadier profiles, check out the 310 resilient stocks with low risk scores to quickly spot companies with more resilient risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com